July 30th 2025
Innovative oncolytic virus therapies transform advanced melanoma treatment, enhance patient outcomes, and overcome resistance to traditional immunotherapies.
July 28th 2025
Bhuvanesh Singh, MD, has big plans for enhancing the skin cancer program at Northwell Health.
July 26th 2025
Experts analyze the evolving landscape of melanoma treatment, highlighting key clinical trials and strategies for optimizing patient outcomes.
July 22nd 2025
The SCIB1/iSCIB1+ cancer vaccines plus nivolumab and ipilimumab improved responses vs nivolumab and ipilimumab alone in patients with melanoma.
The FDA indicated that data from the phase 1/2 IGNYTE trial were not adequate to provide evidence of effectiveness.
Nivolumab Plus Relatlimab Shows Long-Term EFS Benefit in Advanced Melanoma
The B7-H3–low and TIGIT-high biosignatures correlated with superior event-free survival outcomes in those with melanoma treated with the combination.
Advancing Treatment for EGFR Inhibitor–Associated Dermal Toxicities
ATR04-484 showed inhibition of both methicillin-sensitive and methicillin-resistant Staphylococcus aureus bacteria strains, which are associated with rash.
Encorafenib Combo May Limit Recurrence Risk in BRAF V600+ Melanoma
Phase 3 data demonstrate the potential utility of BRAF/MEK inhibition in the adjuvant setting for patients with stage IIB/IIC BRAF V600–mutant melanoma.
FDA Lifts Hold on IFx-2.0 in Advanced/Metastatic Merkel Cell Carcinoma
A phase 3 trial evaluating frontline IFx-2.0 with pembrolizumab in advanced/metastatic Merkel cell carcinoma is planned to start later in June 2025.
RP1/Nivolumab Combo Shows Responses in Advanced Pretreated Melanoma
Data from the IGNYTE trial demonstrate the development of a robust systemic antitumor response following treatment with RP1.
No Improvement in RFS With Adjuvant Nivolumab/Relatlimab in Advanced Melanoma
Compared with nivolumab alone, nivolumab/relatlimab did not improve RFS in patients with resected stage III to IV melanoma.
Nivolumab/Relatlimab Elicit IC Activity in Anti–PD-L1–Refractory Melanoma Brain Mets
The combination elicited a clinical benefit rate of 63.0% and an overall response rate of 22.2% in anti–PD-L1–refractory melanoma with melanoma brain metastases.
Relatlimab Shows Comparable Efficacy to Ipilimumab in Advanced Melanoma
Efficacy across most patient subgroups appeared to be consistent with relatlimab/nivolumab vs ipilimumab/nivolumab in patients with advanced melanoma.
Melphalan/Hepatic Delivery System Demonstrates Benefit in Uveal Melanoma
No treatment-related deaths were observed among patients with metastatic uveal melanoma treated with melphalan and a hepatic delivery system.
Nurulimab/Prolgolimab Yield Superior Efficacy in Advanced Melanoma
The combination of nurulimab plus prolgolimab enhanced PFS, ORR, and DCR compared with prolgolimab monotherapy in unresectable or metastatic melanoma.
ctDNA May Help to Predict Early Recurrence in Stage III Melanoma
ctDNA levels may help to predict early recurrence for patients with stage III melanoma before adjuvant therapy and during follow-up.
DecisionDx-Melanoma Test Accurately Identifies Low-Risk SLN Positivity
All patients identified as low risk for sentinel lymph node positivity with the DecisionDx-Melanoma test had recurrence-free status after 3 years.
Nivolumab Combinations Show Best Treatment Options for Advanced Melanoma
Ahmad Tarhini, MD, PhD, and Hussein A. Tawbi, MD, PhD, discussed data from the RELATIVITY-047 and CheckMate 076 trial for patients with melanoma.
Nivolumab/Relatlimab Shows Sustained Efficacy in Advanced Melanoma
Data from RELATIVITY-047 show consistent benefits with nivolumab/relatlimab across most patient subgroups, including those with BRAF-mutated disease.
Nivolumab/Relatlimab Does Not Meet RFS End Point in Stage III/IV Melanoma
The safety profile of nivolumab plus relatlimab in patients with stage III/IV melanoma was consistent with the known profiles for each individual agent.
Neoadjuvant Pembrolizumab Appears Tolerable in Stage IIIB-D Melanoma
The phase 1/2 KEYMAKER-U02 trial evaluating pembrolizumab alone or as a combination therapy in stage IIIB-D melanoma found no adverse event–related deaths.
RP1/Nivolumab Earns Priority Review in Anti–PD-1 Failed Advanced Melanoma
RP1 with nivolumab elicited an ORR of 38.7% with an acceptable safety profile in patients with advanced melanoma who progressed on anti–PD-1 therapy.
Adjuvant Cemiplimab Boosts DFS in Cutaneous Squamous Cell Carcinoma
Investigators of the phase 3 C-POST trial will continue to follow up with patients and assess the key secondary end point of overall survival.
Nivolumab/Ipilimumab Continues to Show Survival Benefit in Melanoma
The CheckMate 067 trial found that, at a 10-year follow-up, nivolumab/ipilimumab elicited a median OS of 71.9 months in patients with previously untreated, advanced melanoma.
FDA Approves Cosibelimab in Cutaneous Squamous Cell Carcinoma
Cosibelimab has been approved by the FDA as a treatment for patients with cutaneous squamous cell carcinoma.
FDA Assigns BTD and Receives BLA for RP1 Combo in Advanced Melanoma
Vusolimogene oderparepvec in combination with nivolumab has received breakthrough therapy designation from the FDA in advanced melanoma.
IMA203 Shows Frequent, Enduring Responses and Tolerability in Melanoma
Phase 1 data highlight a manageable safety profile with IMA203 among patients with melanoma and other PRAME-positive solid tumors.
Novel Photodynamic Therapy Yields Clearance in Basal Cell Carcinoma
Phase 3 data may support the photodynamic therapy as a noninvasive treatment option for patients with superficial basal cell carcinoma.
PRAME-Targeted Agent Shows Activity in Pretreated Metastatic Melanoma
Phase 1b findings may affirm the therapeutic potential of IMA203 for patients with previously treated metastatic melanoma.
Fianlimab Combo Shows Activity in Advanced Melanoma Subtypes
The safety profile of fianlimab/cemiplimab in a phase 1 trial was consistent with prior reports of cemiplimab monotherapy.
Survival Improves With Atezolizumab Switch Therapy in BRAF+ Melanoma
Phase 2 data also show responses with atezolizumab switch therapy in a population of patients with BRAF V600–positive melanoma.
Pre-BLA Meeting Successful for RP1 Combo in Anti–PD-1–Failed Melanoma
Support for the planned biologics license application comes from data showing a 32.9% response rate with RP1 plus nivolumab for melanoma.
IBI363 Monotherapy Gets Fast Track Status for Advanced Melanoma
Support for the decision follows phase 1 findings evaluating IBI363 in patients with advanced solid tumors presented at the 2024 ESMO Plenary.
Encouraging Tumor Shrinkage Observed in VP-315 for Basal Cell Carcinoma
Preliminary results from part 2 of the phase 2 trial evaluating VP-315 in basal cell carcinoma found no dose-limiting toxicities or treatment-related serious adverse events.
Melanoma Research Pioneer Jeffrey S. Weber, MD, PhD, Dies
The Melanoma Research Alliance mourns the passing of Jeffrey S. Weber, MD, PhD, a pioneer in developing immunotherapy for patients with melanoma.